Vanguard Personalized Indexing Management LLC Acquires 895 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

Vanguard Personalized Indexing Management LLC lifted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 22.6% in the second quarter, according to the company in its most recent filing with the SEC. The fund owned 4,850 shares of the company’s stock after acquiring an additional 895 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Vaxcyte were worth $366,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in PCVX. Parallel Advisors LLC lifted its holdings in shares of Vaxcyte by 155.3% in the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the last quarter. Fifth Third Bancorp bought a new stake in shares of Vaxcyte in the 2nd quarter worth approximately $35,000. Fidelis Capital Partners LLC bought a new stake in shares of Vaxcyte in the 1st quarter worth approximately $37,000. J.Safra Asset Management Corp raised its holdings in Vaxcyte by 649.4% during the 2nd quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after buying an additional 526 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in Vaxcyte during the 2nd quarter valued at $70,000. 96.78% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on PCVX. Leerink Partners upped their price target on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. Jefferies Financial Group upped their price target on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Bank of America upped their price target on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Needham & Company LLC upped their price target on shares of Vaxcyte from $95.00 to $140.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. Finally, Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a report on Tuesday, September 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $147.50.

Vaxcyte Trading Up 1.5 %

Shares of Vaxcyte stock opened at $113.14 on Friday. The company’s fifty day simple moving average is $92.24 and its two-hundred day simple moving average is $77.84. The company has a market cap of $12.63 billion, a P/E ratio of -26.43 and a beta of 0.97. Vaxcyte, Inc. has a 12-month low of $44.20 and a 12-month high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.04. During the same quarter in the previous year, the company earned ($0.70) EPS. Analysts predict that Vaxcyte, Inc. will post -4.33 EPS for the current fiscal year.

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,616 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $76.33, for a total transaction of $199,679.28. Following the transaction, the chief executive officer now directly owns 143,438 shares of the company’s stock, valued at approximately $10,948,622.54. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CEO Grant Pickering sold 2,616 shares of the company’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $76.33, for a total value of $199,679.28. Following the sale, the chief executive officer now directly owns 143,438 shares of the company’s stock, valued at approximately $10,948,622.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $115.94, for a total transaction of $927,520.00. Following the completion of the sale, the chief financial officer now directly owns 90,383 shares in the company, valued at $10,479,005.02. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 78,283 shares of company stock valued at $7,064,138. 3.10% of the stock is currently owned by company insiders.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.